Cargando…

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that possess mutations associated with increased transmission and antibody escape have arisen over the course of the current pandemic. Although the current vaccines have largely been effective against past variants, the n...

Descripción completa

Detalles Bibliográficos
Autores principales: Sievers, Benjamin L., Chakraborty, Saborni, Xue, Yong, Gelbart, Terri, Gonzalez, Joseph C., Cassidy, Arianna G., Golan, Yarden, Prahl, Mary, Gaw, Stephanie L., Arunachalam, Prabhu S., Blish, Catherine A., Boyd, Scott D., Davis, Mark M., Jagannathan, Prasanna, Nadeau, Kari C., Pulendran, Bali, Singh, Upinder, Scheuermann, Richard H., Frieman, Matthew B., Vashee, Sanjay, Wang, Taia T., Tan, Gene S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891085/
https://www.ncbi.nlm.nih.gov/pubmed/35025672
http://dx.doi.org/10.1126/scitranslmed.abn7842
_version_ 1784661785116147712
author Sievers, Benjamin L.
Chakraborty, Saborni
Xue, Yong
Gelbart, Terri
Gonzalez, Joseph C.
Cassidy, Arianna G.
Golan, Yarden
Prahl, Mary
Gaw, Stephanie L.
Arunachalam, Prabhu S.
Blish, Catherine A.
Boyd, Scott D.
Davis, Mark M.
Jagannathan, Prasanna
Nadeau, Kari C.
Pulendran, Bali
Singh, Upinder
Scheuermann, Richard H.
Frieman, Matthew B.
Vashee, Sanjay
Wang, Taia T.
Tan, Gene S.
author_facet Sievers, Benjamin L.
Chakraborty, Saborni
Xue, Yong
Gelbart, Terri
Gonzalez, Joseph C.
Cassidy, Arianna G.
Golan, Yarden
Prahl, Mary
Gaw, Stephanie L.
Arunachalam, Prabhu S.
Blish, Catherine A.
Boyd, Scott D.
Davis, Mark M.
Jagannathan, Prasanna
Nadeau, Kari C.
Pulendran, Bali
Singh, Upinder
Scheuermann, Richard H.
Frieman, Matthew B.
Vashee, Sanjay
Wang, Taia T.
Tan, Gene S.
author_sort Sievers, Benjamin L.
collection PubMed
description Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that possess mutations associated with increased transmission and antibody escape have arisen over the course of the current pandemic. Although the current vaccines have largely been effective against past variants, the number of mutations found on the Omicron (B.1.1.529) spike protein appear to diminish the protection conferred by pre-existing immunity. Using vesicular stomatitis virus (VSV) pseudoparticles expressing the spike protein of several SARS-CoV-2 variants, we evaluated the magnitude and breadth of the neutralizing antibody response over time in individuals after infection and in mRNA-vaccinated individuals. We observed that boosting increases the magnitude of the antibody response to wildtype (D614), Beta, Delta, and Omicron variants; however, the Omicron variant was the most resistant to neutralization. We further observed that vaccinated healthy adults had robust and broad antibody responses whereas responses may have been reduced in vaccinated pregnant women, underscoring the importance of learning how to maximize mRNA vaccine responses in pregnant populations. Findings from this study show substantial heterogeneity in the magnitude and breadth of responses after infection and mRNA vaccination and may support the addition of more conserved viral antigens to existing SARS-CoV-2 vaccines.
format Online
Article
Text
id pubmed-8891085
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-88910852022-03-03 Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses Sievers, Benjamin L. Chakraborty, Saborni Xue, Yong Gelbart, Terri Gonzalez, Joseph C. Cassidy, Arianna G. Golan, Yarden Prahl, Mary Gaw, Stephanie L. Arunachalam, Prabhu S. Blish, Catherine A. Boyd, Scott D. Davis, Mark M. Jagannathan, Prasanna Nadeau, Kari C. Pulendran, Bali Singh, Upinder Scheuermann, Richard H. Frieman, Matthew B. Vashee, Sanjay Wang, Taia T. Tan, Gene S. Sci Transl Med Reports Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that possess mutations associated with increased transmission and antibody escape have arisen over the course of the current pandemic. Although the current vaccines have largely been effective against past variants, the number of mutations found on the Omicron (B.1.1.529) spike protein appear to diminish the protection conferred by pre-existing immunity. Using vesicular stomatitis virus (VSV) pseudoparticles expressing the spike protein of several SARS-CoV-2 variants, we evaluated the magnitude and breadth of the neutralizing antibody response over time in individuals after infection and in mRNA-vaccinated individuals. We observed that boosting increases the magnitude of the antibody response to wildtype (D614), Beta, Delta, and Omicron variants; however, the Omicron variant was the most resistant to neutralization. We further observed that vaccinated healthy adults had robust and broad antibody responses whereas responses may have been reduced in vaccinated pregnant women, underscoring the importance of learning how to maximize mRNA vaccine responses in pregnant populations. Findings from this study show substantial heterogeneity in the magnitude and breadth of responses after infection and mRNA vaccination and may support the addition of more conserved viral antigens to existing SARS-CoV-2 vaccines. American Association for the Advancement of Science 2022-01-13 /pmc/articles/PMC8891085/ /pubmed/35025672 http://dx.doi.org/10.1126/scitranslmed.abn7842 Text en Copyright © 2022, American Association for the Advancement of Science https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reports
Sievers, Benjamin L.
Chakraborty, Saborni
Xue, Yong
Gelbart, Terri
Gonzalez, Joseph C.
Cassidy, Arianna G.
Golan, Yarden
Prahl, Mary
Gaw, Stephanie L.
Arunachalam, Prabhu S.
Blish, Catherine A.
Boyd, Scott D.
Davis, Mark M.
Jagannathan, Prasanna
Nadeau, Kari C.
Pulendran, Bali
Singh, Upinder
Scheuermann, Richard H.
Frieman, Matthew B.
Vashee, Sanjay
Wang, Taia T.
Tan, Gene S.
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
title Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
title_full Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
title_fullStr Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
title_full_unstemmed Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
title_short Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
title_sort antibodies elicited by sars-cov-2 infection or mrna vaccines have reduced neutralizing activity against beta and omicron pseudoviruses
topic Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891085/
https://www.ncbi.nlm.nih.gov/pubmed/35025672
http://dx.doi.org/10.1126/scitranslmed.abn7842
work_keys_str_mv AT sieversbenjaminl antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT chakrabortysaborni antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT xueyong antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT gelbartterri antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT gonzalezjosephc antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT cassidyariannag antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT golanyarden antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT prahlmary antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT gawstephaniel antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT arunachalamprabhus antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT blishcatherinea antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT boydscottd antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT davismarkm antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT jagannathanprasanna antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT nadeaukaric antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT pulendranbali antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT singhupinder antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT scheuermannrichardh antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT friemanmatthewb antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT vasheesanjay antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT wangtaiat antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses
AT tangenes antibodieselicitedbysarscov2infectionormrnavaccineshavereducedneutralizingactivityagainstbetaandomicronpseudoviruses